Clinical Trials
91 trialsNCT03633331 2026-04-29
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03747042 2026-03-16
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT06465368 2025-10-01
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
Pfizer
Phase 2 Completed
NCT02958852 2025-09-10
ABC-SE
Lund University Hospital
Phase 2 Completed
NCT02730429 2025-07-31
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02491983 2024-12-09
PARSIFAL
MedSIR
Phase 2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT01353209 2024-04-17
TRAIL
University of Cincinnati
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT03007979 2024-03-20
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT03936270 2024-02-20
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT03306472 2024-01-30
PIONEER
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Completed
NCT03809988 2023-09-07
PALMIRA
MedSIR
Phase 2 Completed
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT00579826 2023-06-12
Study of Breast Cancer Prevention by Letrozole in High Risk Women
University of Kansas Medical Center
Phase 2 Completed
NCT01698918 2023-05-03
BOLERO-4
Novartis
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00530868 2022-10-21
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT02806050 2022-10-12
Palbociclib and FES PET
University Medical Center Groningen
Phase 2 Completed
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT03628066 2022-04-20
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT02400567 2022-03-15
NeoPAL
UNICANCER
Phase 2 Completed
NCT02296801 2022-01-13
PALLET
NSABP Foundation Inc
Phase 2 Completed
NCT02657928 2021-10-26
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Mayo Clinic
Phase 2 Completed
NCT02742051 2021-09-23
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT01231659 2021-03-26
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT03248427 2021-03-17
CORALLEEN
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01684215 2020-11-23
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT02283658 2020-10-23
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
Phase 2 Completed
NCT02344550 2020-07-30
LEO
Asan Medical Center
Phase 2 Completed
NCT02455154 2020-04-14
COAT
Shanghai Jiao Tong University School of Medicine
Phase 2 Completed
NCT00004251 2020-04-06
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00238316 2020-04-02
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
Canadian Cancer Trials Group
Phase 2 Completed